聚光科技：目前谱康医学和聚致生物对公司整体业务影响较小

Core Viewpoint - The company is focusing on increasing its R&D expense ratio to 18.2% in 2024, with significant investments in high-end instruments and new technologies such as terahertz and gene sequencing, while facing pricing competition from major players like Thermo Fisher [1] Group 1: R&D and Investment - The company plans to allocate 18.2% of its budget to R&D in 2024, emphasizing high-end instruments and new technologies [1] - The company is under pressure from competitors like Thermo Fisher, which are reducing prices [1] Group 2: Domestic Production and Product Impact - The current domestic production rate for core components, such as ion sources and vacuum pumps, has improved, but specific percentages depend on product category and procurement standards [1] - The impact of new products from Pukang Medical and Juzhi Biotechnology on the company's overall business is currently minimal [1]